CRTD4
The cell line is not validated yet.
CRTDi005-A
General
Cell Line |
|
| hPSCreg name | CRTDi005-A |
| Cite as: | CRTDi005-A (RRID:CVCL_YR24) |
| Alternative name(s) |
CRTD4
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
REGUi001-A (IPS4FLV) CRTDi005-B (CRTD5) |
| Last update | 25th May 2021 |
| User feedback | |
Provider |
|
| Generator | Center for Regenerative Therapies Dresden (CRTD) |
| Owner | Center for Regenerative Therapies Dresden (CRTD) |
| Distributors | |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA6689580 |
| Cellosaurus | CVCL_YR24 |
| Wikidata | Q93458861 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | neonate |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA112358183 |
Ethics
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Drs. O.M. Pereira-Smith and James R. Smith at Baylor College of Medicine (1986) |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Alternatives to consent are available? | No |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Do you have obligations to third parties in regard to the use of the cell line? | Yes |
| Please describe: | ATCC is owner of the Fibroblasts used for hiPSC derivation - they need to be informed via their transfer request form of any transfer of a modification (hiPSC) of their material |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | ThermoFisher Scientific |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell line name |
BJ Other names
Derived from same source line (potentially other lot and donor, see below):
|
| Source cell type |
Synonyms
|
| Source cell origin | |
| Source cell type (free text) | ATCC® CRL-2522 |
| Source cell line lot number |
LOT62341989
Derived from same source line lot:
|
| Age of donor (at collection) | neonate |
| Source cell line vendor | ATCC |
| Passage number reprogrammed | ?+2 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
ReLeSR
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
Morphology pictures
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| SOX17 |
Yes |
Morphology
CRTD4-SOX17-488-20X-sb.tif
SOX17 only
CRTD4-SOX17-DAPI-20X.tif
DAPI only
green: SOX17, blue: DAPI
In vitro spontaneous differentiation
| Marker | Expressed |
| ACTA2 (SMA) |
Yes |
Morphology
CRTD4-SMA-488-20X.tif
SMA only
CRTD4-SMA-DAPI-20Xsb.tif
DAPI only
CRTD4-SMA-488+DAPI-20X merged.tif
green: SMA, blue: DAPI
In vitro spontaneous differentiation
| Marker | Expressed |
| TUBB3 (TUJ1) |
Yes |
Morphology
CRTD4-TUJ1-488-10X-3.tif
TUJ1 only
CRTD4-TUJ1-DAPI-10X-3sb.tif
DAPI only
CRTD4-TUJ1-488+DAPI-10X-3sb merged.tif
green: TUJ1, blue: DAPI
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.